Runge H M, Teufel G, Neulen J, Geyer H, Pfleiderer A
Cancer Chemother Pharmacol. 1986;16(1):58-63. doi: 10.1007/BF00255287.
As previously reported, ovarian epithelial carcinomas may respond to endocrine therapy. We examined the direct effect of progesterone, medroxyprogesteroneacetate, gestoneron, 17-beta-estradiol, tamoxifen, 4-OH-tamoxifen, or N-desmethyltamoxifen on the proliferative capacity of ovarian carcinoma cells by means of the colony assay described by Hamburger and Salmon. The growth rate of 25 tested tumors (ascitic fluid, primary tumor, metastases) was 68%. The plating efficiency was 0.078%. Beside the drug testing estrogen and progesterone receptor levels were determined. The inhibition of colony survival was slightest with 17-beta-estradiol, more pronounced with medroxyprogesteroneacetate, gestoneron, N-desmethyltamoxifen, and progesterone, and greatest with 4-OH-tamoxifen and tamoxifen. Significant and dose-dependent inhibition of greater than 70% was observed with tamoxifen and 4-OH-tamoxifen in 80% of the tested tumors. There was no significant correlation between the in vitro responsiveness and the level of hormonal act not only via an estrogen receptor but also via an antiestrogen-binding site.
如先前报道，卵巢上皮癌可能对内分泌治疗有反应。我们通过汉堡和萨蒙描述的集落试验，研究了孕酮、醋酸甲羟孕酮、孕三烯酮、17-β-雌二醇、他莫昔芬、4-羟基他莫昔芬或N-去甲基他莫昔芬对卵巢癌细胞增殖能力的直接影响。25个受试肿瘤（腹水、原发肿瘤、转移灶）的生长率为68%。接种效率为0.078%。除了进行药物测试外，还测定了雌激素和孕酮受体水平。17-β-雌二醇对集落存活的抑制作用最小，醋酸甲羟孕酮、孕三烯酮、N-去甲基他莫昔芬和孕酮的抑制作用更明显，4-羟基他莫昔芬和他莫昔芬的抑制作用最大。在80%的受试肿瘤中，他莫昔芬和4-羟基他莫昔芬观察到大于70%的显著且剂量依赖性抑制。体外反应性与激素活性水平之间不仅通过雌激素受体，而且通过抗雌激素结合位点均无显著相关性。
